• Kushal T Kadakia, Vinay K Rathi, Sanket S Dhruva, Joseph S Ross, and Harlan M Krumholz.
• Harvard Medical School, Boston, Massachusetts (K.T.K.).
• Ann. Intern. Med. 2024 Nov 1; 177 (11): 155815651558-1565.

AbstractNearly all medical devices reviewed by the U.S. Food and Drug Administration (FDA) are authorized via the 510(k) clearance process. Established in 1976, this review pathway bases authorizations on the comparability of new devices to previously authorized devices ("predicates"). This evaluation usually does not require clinical evidence of safety and effectiveness. Advocates of the 510(k) clearance process tout its support for device innovation and rapid market access, and critics of the 510(k) clearance process express that it may inadequately protect patient safety. In September 2023, the FDA issued 3 guidance documents that, if finalized, would significantly change medical device regulation. This article provides clinical and regulatory context for the proposed guidance documents, which focus on predicate selection, clinical testing requirements, and implantable devices, and identifies opportunities for further reforms that promote transparency and patient safety.

20 keywords...

hide…